104618-31-7

Basic information

• Product Name: 4-(Phthalimide)cyclohexanol
• Synonyms: 2-(4-Hydroxycyclohexyl)-1H-isoindole-1,3(2H)-dione;2-(4-Hydroxycyclohexyl)isoindol-1,3-dione;4-(Phthalimide)cyclohexanol;2-(4-Hydroxycyclohexyl)isoindoline-1,3-dione;1H-Isoindole-1,3(2H)-dione,2-(4-hydroxycyclohexyl)
• CAS NO: 104618-31-7
• Molecular Formula: C₁₄H₁₅NO₃
• Molecular Weight: 245.277
• EINECS: 1533716-785-6
• Mol File: 104618-31-7.mol

Chemical Properties

• Boiling Point: 410.1±38.0 °C(Predicted)
• Appearance: /
• Density: 1.365
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.99±0.40(Predicted)
• CAS DataBase Reference: 4-(Phthalimide)cyclohexanol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Phthalimide)cyclohexanol(104618-31-7)
• EPA Substance Registry System: 4-(Phthalimide)cyclohexanol(104618-31-7)

Safety Data

• Hazardous Substances Data: 104618-31-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-(Phthalimide)cyclohexanol is used as a building block for [various organic synthesis processes] because of [its reactivity in cross-coupling reactions and the presence of a hydroxyl group that can participate in various chemical reactions].
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-(Phthalimide)cyclohexanol is used as an intermediate for [the synthesis of specific pharmaceutical compounds] due to [its structural features that can be further modified to create bioactive molecules].
Used in Chemical Research:
4-(Phthalimide)cyclohexanol is utilized as a research compound for [exploring new chemical reactions and mechanisms], given [its unique combination of phthalimide and cyclohexanol functionalities].
Used in Material Science:
In material science, 4-(Phthalimide)cyclohexanol is used as a component in [the development of new materials with specific properties], such as [enhanced stability or reactivity in certain conditions], owing to [its structural characteristics and potential for modification].

InChI:InChI=1S/C14H15NO3/c16-10-7-5-9(6-8-10)15-13(17)11-3-1-2-4-12(11)14(15)18/h1-4,9-10,16H,5-8H2

Upstream product

• 136918-14-4 phthalimide 
• 85-44-9 phthalic anhydride 
• 22509-74-6 N-ethoxycarbonylphthalimide 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 6850-65-3 p-hydroxycyclohexylamine 

Downstream Products

• 952589-02-5 4-[4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-cyclohexyloxy]-benzoic acid ethyl ester 
• 1418143-14-2 4-(1,3-dioxoisoindolin-2-yl)cyclohexane-1-sulfonic acid 
• 1418143-15-3 4-(1,3-dioxoisoindolin-2-yl)cyclohexane-1-sulfonyl chloride 
• 1418143-16-4 4-(1,3-dioxoisoindolin-2-yl)cyclohexane-1-sulfonamide 
• 854443-96-2 4-aminocyclohexane-1-sulfonamide 
• 1418142-73-0 4-((3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexane-1-sulfonamide 
• 1418143-13-1 S-(4-(1,3-dioxoisoindolin-2-yl)cyclohexyl)ethanethioate 
• 1342811-43-1 C₁₉H₁₇BrN₄O₂ 
• 1342949-97-6 C₂₀H₁₈BrN₃O₂ 
• 1342949-96-5 C₂₀H₁₈BrN₃O₂ 
• 1342810-88-1 2-{4-[2-(6-bromopyridin-2-yl)hydrazineylidene]cyclohexyl}isoindoline-1,3-dione 
• 146993-12-6 BRL 56905 hydrochloride 
• 104618-32-8 2-(4-oxocyclohexyl)-1H-isoindole-1,3(2H)-dione 
• 1073973-07-5 2-(4-Methoxy-cyclohexyl)-isoindole-1,3-dione 

Relevant articles and documents

Discovery of Isoxazole Amides as Potent and Selective SMYD3 Inhibitors

We report herein the discovery of isoxazole amides as potent and selective SET and MYND Domain-Containing Protein 3 (SMYD3) inhibitors. Elucidation of the structure-activity relationship of the high-throughput screening (HTS) lead compound 1 provided potent and selective SMYD3 inhibitors. The SAR optimization, cocrystal structures of small molecules with SMYD3, and mode of inhibition (MOI) characterization of compounds are described. The synthesis and biological and pharmacokinetic profiles of compounds are also presented.

Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

HETEROCYCLIC PROTEIN KINASE INHIBITORS

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

Tetrahydroindole and Tetrahydroindazole Derivatives

The invention provides indole and indazole compounds of Formula (I) or pharmaceutically acceptable salts thereof which are useful for treating and/or preventing diseases and/or disorders ameliorated by the inhibition of Heat-Shock Protein 90. The invention further provides pharmaceutical compositions comprising compounds of Formula (I) and methods of preparing compounds of Formula (I).

11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS

A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxy-steroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

IMPROVED PROCESS FOR THE PREPARATION OF BIOLOGICALLY ACTIVE TETRAHYDROBENZTHIAZOLE DERIVATIVE

Improved process for the preparation of the intermediate compound of formula II for formation pramipezole of formula (I) as well as the biological active tetrahydrobenzothiazole compound of formula (I) and/or its pharmaceutically acceptable salts or solvates.

Arylsulphonyl substituted-tetrahydro- and hexahydro-carbazoles

The invention provides compounds of formula I for use in treating conditions in which 5-HT6 receptors are involved such as in anxiety, depression, schizophrenia, Alzheimer's disease, stress-related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, epilepsy, and other CNS disorders.

Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT1 agonist use thereof

Use of a compound of general formula (I): STR1 wherein R1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C1-6 alkyl, C1-6 alkoxy, arylC1-6 alkoxy, --CO2 R4, --(CH2)n CN, --(CH2)n CONR5 R6, --(CH2)n SO2 NR5 R6, C1-6 alkanoylamino(CH2)n, or C1-6 alkylsulphonylamino(CH2)n ; R4 represents hydrogen, C1-6 alkyl or arylC1-6 alkyl; R5 and R6 each independently represent hydrogen or C1-6 alkyl, or R5 and R6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R2 and R3 each independently represent hydrogen, C1-6 alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.